Noushin Afshar Moghaddam - Dept. of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Parvin Mahsoni - Dept. of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Parvin Rajabi - Dept. of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Amir Pooyan Tabibi - Dept. of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Objective: To review Her-2/neu and Tp53 status and their correlation with all other prognostic clinicopathologic features of infiltrative ductal breast carcinomas.Materials and Methods: This cross sectional study was performed on 139 patients with infiltrative ductal breast carcinoma who were diagnosed between May 2000 and March 2006 at the surgery andpathology departments of Alzahra Hospital, Isfahan, Iran. Immunostaining (IHC) for Tp53 andHer-2/neu were performed on formalin-fixed, paraffin-embedded tissues based on an avidin-biotinperoxidase complex technique. The relationship of these markers with clinicpathologic parametersincluding age, axillary lymph nodes status, tumor size and histological grade were evaluated.Results: It was found out that Her-2/neu-positive cases were greater among metastatic lymph nodes than in patients without metastasis, however it was not significant (p=0.1). A significant associationwas also observed between Her-2/neu status and tumor grading (p=0.01). On the contrary, noassociation was found with other clinicpathologic parameters. In this study, Tp53 presentation in high-grade carcinomas was significantly more as compared to low grade ones (p=0.03). A significantassociation was also observed between Tp53 and tumor size (p =0.01). There was no association withmenopausal status and lymph node status. Conclusion: IHC determined that Her-2/neu and Tp53 expressions are not associated with nodaland menopause status. Conversely, a correlation was found between Her-2/neu, Tp53 expressions and high histological grade of tumor. However, to validate these findings, long-term prospective studies on patients’ survival are necessary.

Her-2 proto oncogene protein, Tp53 protein, Mammary ductal carcinoma, Lymphatic Metastasis, Menopause